Amphetamine Stimulant Prodrug denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Amphetamine Stimulant Prodrugs as Experimental

Cigna's experimental/investigational denial for an amphetamine prodrug most often arises in one of two scenarios: (1) the drug is being used for an indication not listed in its FDA-approved labeling, and Cigna's coverage policy classifies that particular off-label use as lacking sufficient clinical evidence; or (2) there is a plan-level exclusion for a specific prodrug formulation that Cigna's system treats as not yet having established clinical evidence for the submitted diagnosis. Understanding the exact basis matters because the appeal argument differs significantly between these two situations.

## Why This Denial Is Appealable

Experimental/investigational denials are among the most commonly reversed denial types in external review. Under ACA §2719 and ERISA §503, an IRO must evaluate the denial using evidence-based clinical standards independent of the insurer's internal policy — and IRO reviewers regularly find that stimulant prodrugs used for well-established psychiatric indications do not meet the clinical definition of "experimental." The external-review window is approximately four months from the denial notice. Expedited review is available if delay would seriously jeopardize health. Many state insurance codes also have specific provisions for mental-health-parity compliance that reinforce the right to appeal.

## The Concrete Appeal Process

1. Obtain Cigna's coverage policy. Request the specific coverage determination document used to classify this use as experimental. 2. Identify the clinical evidence standard Cigna applied. The policy will cite the evidentiary threshold — your appeal should demonstrate that available evidence meets it. 3. File the internal appeal with literature support and a prescriber letter. 4. Invoke mental health parity if applicable: if Cigna covers analogous medications for other conditions without an experimental designation, parity law may prohibit this restriction. 5. External review is highly recommended given IRO reversal rates for this denial type.

## Documentation to Gather

• FDA prescribing label: Confirms the approved indications and establishes the baseline for what is and is not off-label.
• Peer-reviewed literature and/or compendium support: Published evidence and any relevant professional society guideline (e.g., the applicable AAP, APA, or AAFP guideline) supporting the use for the patient's diagnosis.
• Prescriber medical-necessity letter: Explains why this specific use is consistent with accepted clinical practice and why withholding it constitutes a departure from the standard of care.
• Mental-health-parity analysis: If stimulants are covered for other indications without an experimental barrier, document the disparity.

## Criteria-Mapping Strategy

Map Cigna's "experimental" definition criteria against available clinical evidence point by point. Reviewers are looking for: Is there FDA approval or substantial peer-reviewed support? Do recognized professional societies endorse this use? Is this use already standard clinical practice? Address each question with a specific citation or document.